A Real-World Multicenter Retrospective Study of Treatment Outcomes with Ipilimumab and Nivolumab in Mesothelioma

被引：0
|
作者：
Sridhar, A. [1 ]
Schwecke, A. [2 ]
Durer, S. [3 ]
Hsu, M. L. [4 ,5 ]
Singh, A. [1 ]
Mansfield, A. S. [1 ]
Lou, Y. [6 ]
Molina, J. R. [1 ]
Leventakos, K. [1 ]
Dimou, A. [1 ]
Manochakian, R. [7 ]
Shanshal, M. [1 ]
Ernani, V. [8 ]
Moffett, J. N. [1 ]
Luce, A. [2 ]
Parikh, K. [2 ]
机构：
[1] Mayo Clin, Rochetser, MN USA
[2] Mayo Clin, Rochester, MN USA
[3] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[4] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[5] Case Western Reserve Univ, Cleveland, OH USA
[6] Mayo Clin, Jacksonville, FL USA
[7] Mayo Clin, Rochester, FL USA
[8] Mayo Clin, Phoenix, AZ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
DDR mutations; lung cancer; socioeconomic factors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14A.14
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [21] Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study
    Izumi, Keita
    Inoue, Masaharu
    Washino, Satoshi
    Shirotake, Suguru
    Kagawa, Makoto
    Takeshita, Hideki
    Miura, Yuji
    Hyodo, Yoji
    Oyama, Masafumi
    Kawakami, Satoru
    Miyagawa, Tomoaki
    Saito, Kazutaka
    Kageyama, Yukio
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 714 - 721
  • [22] Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
    Schmid, S.
    Holer, L.
    Frueh, M.
    Koster, K-L.
    Rothschild, S. I.
    Britschgi, C.
    Boos, L.
    Frehner, L.
    Almeida, S. Cardoso
    Metaxas, Y.
    Mark, M. T.
    Froesch, P. R.
    Janthur, W-D.
    Allemann, A. T.
    Waibel, C.
    Vonder Muhll-Schill, C.
    Cerciello, F. W. F.
    Mauti, L. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1133 - S1134
  • [23] Real-world outcomes of nivolumab in adjuvant melanoma treatment in Australia
    Atkinson, Victoria
    Brady, Benjamin
    Peters, Geoffrey
    Azer, Mary
    Bakharevski, Olga
    McDonald, Laura
    Vouk, Katja
    Parente, Phillip
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 34 - 35
  • [24] Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study
    Oka, Yurie
    Matsumoto, Jun
    Takeda, Tatsuaki
    Iwata, Naohiro
    Niimura, Takahiro
    Ozaki, Aya Fukuma
    Bekku, Kensuke
    Hamano, Hirofumi
    Araki, Motoo
    Ishizawa, Keisuke
    Zamami, Yoshito
    Ariyoshi, Noritaka
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (03) : 745 - 750
  • [25] Real world toxicity data for the use of ipilimumab plus nivolumab in malignant mesothelioma
    McGrath, Harriet
    Anam, Kaiser
    Morton, Cienne
    Gennatas, Spyridon
    Ghosh, Sharmistha
    Karapanagiotou, Eleni
    Georgiou, Alexandros
    Spicer, James
    LUNG CANCER, 2024, 190
  • [26] Real-World Effectiveness and Safety of Nivolumab in Special Subgroups of NSCLC pts: A Multicenter-Retrospective Study
    Kitazono, Satoru
    Morita, Ryo
    Okishio, Kyoichi
    Shimizu, Junichi
    Saito, Haruhiro
    Sakai, Hiroshi
    Kim, Young Hak
    Hataji, Osamu
    Yomota, Makiko
    Aoe, Keisuke
    Kanai, Osamu
    Kumagai, Toru
    Kibata, Kayoko
    Tsukamoto, Hiroaki
    Oizumi, Satoshi
    Tomii, Keisuke
    Tanaka, Hiroshi
    Mizuno, Keiko
    Hoshiyama, Hirotoshi
    Ochi, Kenya
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2019, 30 : 110 - 110
  • [27] Real-World Effectiveness and Safety of Nivolumab in NSCLC pts in Japan: A Multicenter-Retrospective Observational Study
    Saito, Haruhiro
    Morita, Ryo
    Okishio, Kyoichi
    Shimizu, Junichi
    Sakai, Hiroshi
    Kim, Young Hak
    Hataji, Osamu
    Yomota, Makiko
    Nishio, Makoto
    Aoe, Keisuke
    Kanai, Osamu
    Kumagai, Toru
    Kibata, Kayoko
    Tsukamoto, Hiroaki
    Oizumi, Satoshi
    Tomii, Keisuke
    Tanaka, Hiroshi
    Mizuno, Keiko
    Hoshiyama, Hirotoshi
    Ochi, Kenya
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2019, 30
  • [28] Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
    Asher, Nethanel
    Ben-Betzalel, Guy
    Lev-Ari, Shaked
    Shapira-Frommer, Ronnie
    Steinberg-Silman, Yael
    Gochman, Neta
    Schachter, Jacob
    Meirson, Tomer
    Markel, Gal
    CANCERS, 2020, 12 (08) : 1 - 18
  • [29] Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
    Assie, Jean-Baptiste
    Crepin, Florian
    Grolleau, Emmanuel
    Canellas, Anthony
    Geier, Margaux
    Grebert-Manuardi, Aude
    Akkache, Nabila
    Renault, Aldo
    Hauss, Pierre-Alexandre
    Sabatini, Marielle
    Bonnefoy, Valentine
    Cortot, Alexis
    Wislez, Marie
    Gauvain, Clement
    Chouaid, Christos
    Scherpereel, Arnaud
    Monnet, Isabelle
    CANCERS, 2022, 14 (06)
  • [30] A real-world experience of nivolumab in advanced malignant mesothelioma (MM).
    Hamad, Hussein
    Shafi, Sumaira
    De Rosen, Veronica Lenge
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345